October 12, 2026 | Medical Device Industry Briefing | Issue No. 4337
Deep Dive: AI That 'Reads' Genes From a Single Slide
On October 10, 2026, a team led by Zhong Nanshan—the renowned Chinese respiratory specialist—jointly with KingMed Diagnostics Group Co., Ltd. (NYSE: 603882), unveiled DeepGEM 2.0, a multimodal large language model designed to predict lung cancer-related gene mutations directly from routine digital pathology slides.
The model, developed with the National Respiratory Medicine Center at the First Affiliated Hospital of Guangzhou Medical University, requires no additional tissue sampling. It analyzes standard hematoxylin-and-eosin (H&E) stained slides and outputs predictions on gene mutation probability and spatial distribution within the tissue—results delivered in as little as one minute.
Version 2.0 represents a significant upgrade. Trained on nearly 8,000 digital pathology slides collected from 31 provinces across China, the model now predicts 12 lung cancer-related genes—double the six covered in its predecessor. The newly added targets include BRAF, ERBB2, FGFR, MET, NTRK, and RET.
A multi-center, prospective, randomized controlled study has been launched, planning to enroll nearly 1,000 non-small cell lung cancer patients predicted positive by DeepGEM 2.0 across 50 medical institutions. The model will also be deployed in lightweight form to more than 500 healthcare facilities. According to the development team, the "AI initial screening plus targeted gene verification" approach could reduce lung cancer genetic testing costs to the range of several hundred Chinese yuan (roughly $50–$100 USD).
Source: China News Service, October 10, 2026
Policy Watch: EU Tightens Oversight on High-Risk IVDs
Coinciding with the European Day of Organ, Tissue and Cell Donation on October 10, the EU Health and Digital Executive Agency (HaDEA) announced progress on the EU4Health-funded EURL-IVD.3 project, themed "Safe testing for safer donations."
The project targets Class D high-risk in vitro diagnostic (IVD) products under the In Vitro Diagnostic Regulation (IVDR) (EU) 2017/744. These include tests used to detect infectious disease pathogens and assess the safety of donated blood, organs, tissues, and cells.
Under the new framework, notified bodies must now request independent verification from EU Reference Laboratories (EURLs) for designated Class D IVDs. The EURLs will verify device performance claims made by manufacturers and conduct batch testing to ensure consistent quality across production lots. This requirement extends the work initiated under EURL-IVD.1 and EURL-IVD.2.
For manufacturers exporting transfusion screening and infectious disease testing products to Europe, EURL verification and batch testing must now be factored into CE marking registration timelines and budgets.
Source: HaDEA (EU Health and Digital Executive Agency), October 10, 2026
Industry: World's First Retinal Hole Sealing Gel Approved in China
Haohai Biotech (688366.SH), through its subsidiary Qisheng Bio, has developed the world's first approved retinal hole sealing gel, branded "Shiyouning" (intraocular cross-linked sodium hyaluronate gel). The product received Class III medical device registration from China's National Medical Products Administration (NMPA) in March 2026.
The first batch of surgeries using the new gel was performed at Tianjin Medical University Eye Hospital. Clinical trials were conducted across eight ophthalmology centers in China, enrolling 326 patients.
Traditional rhegmatogenous retinal detachment surgery requires intraocular filling with gas or silicone oil to press the retinal hole closed, forcing patients to maintain a prone position for extended periods post-surgery. Those with silicone oil fillings often require a second surgery for removal. The new gel provides precise local sealing at the retinal hole, enabling faster visual recovery without the need for prone positioning.
Source: Jinyun · Beifang Net, October 10, 2026
Industry: Haier Biotech Leads World's First International Standard for Medical Automated Cold Storage
Haier Biotech (688139.SH) has successfully led the initiation(project initiation) of IEC 63590-2-3, titled "Medical low-temperature storage equipment—Part 2-3: Performance requirements and test methods for (semi-)automatic refrigerated and frozen storage." This is reportedly the world's first international standard specifically addressing performance requirements and test methods for medical automated cold storage facilities.
The standard will establish unified requirements and testing methods covering storage temperature classification, temperature performance, automation performance, and information technology performance. It aims to provide international technical guidance for the safe storage of biosamples, pharmaceuticals, blood products, and vaccines.
A Haier expert will serve as convener of the project committee's task force, with participation from experts in China, Switzerland, Germany, the United Kingdom, South Korea, and France. Haier Biotech has 20 years of experience in low-temperature storage, holds over 1,700 patents, and sells products in more than 160 countries and regions.
Source: Haier Group Official Website, October 10, 2026
Global: ZEISS Acquires Scottish Holographics Firm
On October 8, German optics giant ZEISS announced the acquisition of Ceres Holographics, a holographic technology company headquartered in Livingston, Scotland. The move aims to accelerate the industrialization of holographic technology.
Ceres Holographics specializes in holographic optical elements (HOE), holographic recording materials, and display technology. Its capabilities enable light waveguides, diffraction, and focusing functions within thin, lightweight structures. Applications span augmented reality (AR) waveguide displays, heads-up displays (HUD), automotive and industrial optics, as well as medical optical imaging, ophthalmic equipment, and miniaturized optical sensing.
ZEISS brings deep expertise in optics, semiconductor metrology, and medical technology (including ophthalmic diagnostics and surgical microscopes). The integration of Ceres' holographic capabilities is expected to accelerate the transition from laboratory research to scaled manufacturing.
Source: ZEISS Official Website, October 8, 2026
Global: Lifotronic's HbA1c System Clears FDA 510(k)
Shenzhen Lifotronic Technology Co., Ltd. (688389.SH) announced on October 9 that its H100Plus Hemoglobin Detection System has received U.S. FDA 510(k) clearance (Reference Number: K260468), with the FDA decision date of October 2, 2026. The product is classified as Class II.
The system is intended for in vitro quantitative detection of glycosylated hemoglobin (HbA1c) in human whole blood. HbA1c reflects average blood glucose levels over the preceding two to three months and is internationally recognized as a core indicator for long-term diabetes monitoring and auxiliary diagnosis, recommended by WHO and ADA guidelines.
The company cautioned that overseas regulatory policies and market conditions remain subject to change, and actual sales performance in the U.S. market carries uncertainty.
Source: Juchao Information Network / FDA, October 9, 2026
Global: UK's Sava Raises $36M for Needle-Free CGM
UK-based medical device company Sava Technologies has completed a $36 million Series B funding round, led by blood glucose monitoring specialist Ascensia Diabetes Care. The company's cumulative funding now stands at $68 million.
Sava is developing a needle-free continuous glucose sensor. Its microsensor penetrates the skin to a depth approximately one-tenth that of existing continuous glucose monitoring (CGM) products, making wear nearly painless. Ascensia has signed an exclusive agreement to commercialize the product starting in Europe once it obtains CE marking.
The company plans to conduct pivotal clinical studies this year, targeting CE mark approval and market launch within 18 to 24 months. The global CGM market, currently dominated by Abbott (FreeStyle Libre) and Dexcom, was valued at approximately $8 billion in 2025, according to Bizztor.
Source: Bizztor, October 9, 2026
AI & Devices: FDA Clears AI Tool for Autism Screening in Children
On October 8, Argus Cognitive announced that its Neurora platform has received FDA 510(k) clearance (Reference Number: K260064) for AI-assisted diagnosis of autism spectrum disorder (ASD) in children aged 18 months to 12 years.
The product is designed to assist clinicians in evaluating children for ASD, with the goal of shortening the wait time between when parents first notice developmental concerns and when a formal diagnosis is obtained. Current autism diagnosis relies heavily on specialist observation of behavior and standardized assessment scales—processes that are subjective and constrained by limited specialist availability.
By introducing objective, AI-driven screening, the tool aims to enable primary care settings to conduct initial assessments, rather than replacing physician diagnosis. Regulatory scrutiny for pediatric and behavioral health AI remains high, with particular attention to appropriate patient populations, data bias, and clinical validation study design.
Source: Business Wire / FDA 510(k) Database, October 8, 2026
Editor's Note: The Next Phase of Medical AI—Evidence Over Parameters
The launch approach of DeepGEM 2.0 is noteworthy: rather than leading with model size or parameter counts, the team immediately outlined a "50-hospital, nearly 1,000-patient prospective randomized controlled study" roadmap. Medical AI has reached a point where parameters and benchmark rankings carry diminishing appeal. What truly determines hospital adoption comes down to two things: multi-center, prospective clinical evidence, and the ability to secure regulatory clearance and integrate into clinical pathways.
KingMed Diagnostics holds vast national pathology slide collections and testing networks; the Zhong Nanshan team provides clinical credibility. This combination of "data plus clinical validation" may prove more effective for medical AI deployment than pure algorithmic superiority.
Source: Osmunda Analysis
Sources: China News Service · HaDEA · Jinyun · Beifang Net · Haier Group · Bizztor · ZEISS · Juchao Information Network · U.S. FDA · Business Wire · Osmunda
Disclaimer: This briefing is sourced from publicly available information and is intended for reference by medical device industry professionals only. It does not constitute legal, regulatory, or compliance advice. Please refer to official sources for authoritative information.